Mesoblast (MEOBF) Stock Price, News & Analysis

Company Overview

Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.

The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan. Additional programs in advanced clinical stages include therapies for chronic heart failure, acute respiratory distress syndrome, and chronic lower back pain. Mesoblast’s allogeneic approach is designed to enable “off-the-shelf” dosing, offering potential advantages in consistency, scalability, and rapid availability compared to patient-specific cell therapies.

Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast operates research, development, and manufacturing facilities across multiple geographies, including the United States and Europe. The company has established strategic collaborations and licensing agreements with leading pharmaceutical companies and health authorities worldwide to advance development programs and secure regulatory approvals. Mesoblast’s global footprint supports its commitment to making cell therapy more broadly accessible to patients in need.

Mesoblast’s leadership team comprises experienced professionals from the biotechnology and pharmaceutical industries. The company was co-founded by Dr. Silviu Itescu, who has led the scientific strategy and clinical development efforts. Under the guidance of its executive management and board of directors, Mesoblast continues to expand its pipeline and pursue regulatory milestones, with a focus on delivering transformative medicines for serious diseases.

Key Stats

• Today's Range: $1.89 to $1.89
• 50-Day Range: $1.55 to $1.89
• 52-Week Range: $1.30 to $2.59
• Volume: N/A
• Average Volume: 1,810 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Mesoblast Stock Analysis - MarketRank™

Mesoblast scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Mesoblast.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Mesoblast is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mesoblast is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mesoblast has recently increased by 3.05%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mesoblast does not currently pay a dividend.

Dividend Growth

Mesoblast does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: N/A

News Sentiment

Mesoblast has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mesoblast this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mesoblast insiders have not sold or bought any company stock.

Percentage Held by Institutions

27.35% of the stock of Mesoblast is held by institutions.

Company Calendar

• Today: 8/12/2026
• Next Earnings (Estimated): 9/02/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MEOBF
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A